annual EBITDA:
$255.74M+$346.08M(+383.08%)Summary
- As of today (July 1, 2025), PTGX annual EBITDA is $255.74 million, with the most recent change of +$346.08 million (+383.08%) on December 31, 2024.
- During the last 3 years, PTGX annual EBITDA has risen by +$378.81 million (+307.80%).
- PTGX annual EBITDA is now at all-time high.
Performance
PTGX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$19.07M-$146.39M(-114.98%)Summary
- As of today (July 1, 2025), PTGX quarterly EBITDA is -$19.07 million, with the most recent change of -$146.39 million (-114.98%) on March 1, 2025.
- Over the past year, PTGX quarterly EBITDA has dropped by -$225.62 million (-109.23%).
- PTGX quarterly EBITDA is now -109.23% below its all-time high of $206.54 million, reached on March 31, 2024.
Performance
PTGX quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$30.12M-$225.62M(-88.22%)Summary
- As of today (July 1, 2025), PTGX TTM EBITDA is $30.12 million, with the most recent change of -$225.62 million (-88.22%) on March 1, 2025.
- Over the past year, PTGX TTM EBITDA has dropped by -$121.27 million (-80.10%).
- PTGX TTM EBITDA is now -88.22% below its all-time high of $255.74 million, reached on December 31, 2024.
Performance
PTGX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
PTGX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +383.1% | -109.2% | -80.1% |
| 3 y3 years | +307.8% | +6.0% | +125.1% |
| 5 y5 years | +440.1% | -0.4% | +144.2% |
PTGX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +299.8% | -109.2% | +54.1% | -88.2% | +120.1% |
| 5 y | 5-year | at high | +299.8% | -109.2% | +54.1% | -88.2% | +120.1% |
| alltime | all time | at high | +299.8% | -109.2% | +54.1% | -88.2% | +120.1% |
PTGX EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$19.07M(-115.0%) | $30.12M(-88.2%) |
| Dec 2024 | $255.74M(-383.1%) | $127.32M(-412.0%) | $255.74M(+67.9%) |
| Sep 2024 | - | -$40.81M(+9.3%) | $152.30M(-2.1%) |
| Jun 2024 | - | -$37.32M(-118.1%) | $155.61M(+2.8%) |
| Mar 2024 | - | $206.54M(+764.9%) | $151.39M(-267.6%) |
| Dec 2023 | -$90.34M(-29.4%) | $23.88M(-163.7%) | -$90.34M(-39.7%) |
| Sep 2023 | - | -$37.50M(-9.7%) | -$149.90M(+4.2%) |
| Jun 2023 | - | -$41.53M(+18.0%) | -$143.85M(+0.7%) |
| Mar 2023 | - | -$35.19M(-1.4%) | -$142.91M(+11.6%) |
| Dec 2022 | -$128.00M(+4.0%) | -$35.68M(+13.4%) | -$128.00M(-0.4%) |
| Sep 2022 | - | -$31.45M(-22.5%) | -$128.53M(-1.4%) |
| Jun 2022 | - | -$40.60M(+100.2%) | -$130.30M(+8.6%) |
| Mar 2022 | - | -$20.28M(-44.0%) | -$119.95M(-2.5%) |
| Dec 2021 | -$123.07M(+100.0%) | -$36.20M(+9.0%) | -$123.07M(+17.4%) |
| Sep 2021 | - | -$33.22M(+9.8%) | -$104.84M(+33.2%) |
| Jun 2021 | - | -$30.25M(+29.3%) | -$78.74M(+19.4%) |
| Mar 2021 | - | -$23.40M(+30.2%) | -$65.92M(+7.1%) |
| Dec 2020 | -$61.52M(-18.2%) | -$17.97M(+152.4%) | -$61.52M(+3.7%) |
| Sep 2020 | - | -$7.12M(-59.2%) | -$59.36M(-12.9%) |
| Jun 2020 | - | -$17.44M(-8.2%) | -$68.11M(-15.8%) |
| Mar 2020 | - | -$19.00M(+20.3%) | -$80.86M(+7.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | -$75.19M(+91.8%) | -$15.80M(-0.5%) | -$75.19M(+4.2%) |
| Sep 2019 | - | -$15.87M(-47.4%) | -$72.12M(+10.1%) |
| Jun 2019 | - | -$30.18M(+126.4%) | -$65.49M(+47.6%) |
| Mar 2019 | - | -$13.33M(+4.7%) | -$44.38M(+13.2%) |
| Dec 2018 | -$39.20M(+7.2%) | -$12.74M(+37.9%) | -$39.20M(+35.6%) |
| Sep 2018 | - | -$9.24M(+1.9%) | -$28.91M(+17.8%) |
| Jun 2018 | - | -$9.07M(+11.3%) | -$24.55M(-19.6%) |
| Mar 2018 | - | -$8.15M(+231.9%) | -$30.52M(-16.5%) |
| Dec 2017 | -$36.55M(+13.0%) | -$2.46M(-49.6%) | -$36.55M(-19.5%) |
| Sep 2017 | - | -$4.87M(-67.6%) | -$45.42M(-4.6%) |
| Jun 2017 | - | -$15.04M(+6.0%) | -$47.60M(+20.3%) |
| Mar 2017 | - | -$14.19M(+25.3%) | -$39.57M(+22.3%) |
| Dec 2016 | -$32.35M(+122.4%) | -$11.32M(+60.5%) | -$32.35M(+24.7%) |
| Sep 2016 | - | -$7.05M(+0.7%) | -$25.94M(+13.5%) |
| Jun 2016 | - | -$7.00M(+0.5%) | -$22.86M(+21.1%) |
| Mar 2016 | - | -$6.97M(+41.8%) | -$18.88M(+29.8%) |
| Dec 2015 | -$14.55M(+60.5%) | -$4.91M(+23.7%) | -$14.55M(+51.0%) |
| Sep 2015 | - | -$3.97M(+31.1%) | -$9.63M(+70.2%) |
| Jun 2015 | - | -$3.03M(+15.2%) | -$5.66M(+115.2%) |
| Mar 2015 | - | -$2.63M | -$2.63M |
| Dec 2014 | -$9.06M | - | - |
FAQ
- What is Protagonist Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Protagonist Therapeutics?
- What is Protagonist Therapeutics annual EBITDA year-on-year change?
- What is Protagonist Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Protagonist Therapeutics?
- What is Protagonist Therapeutics quarterly EBITDA year-on-year change?
- What is Protagonist Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Protagonist Therapeutics?
- What is Protagonist Therapeutics TTM EBITDA year-on-year change?
What is Protagonist Therapeutics annual EBITDA?
The current annual EBITDA of PTGX is $255.74M
What is the all time high annual EBITDA for Protagonist Therapeutics?
Protagonist Therapeutics all-time high annual EBITDA is $255.74M
What is Protagonist Therapeutics annual EBITDA year-on-year change?
Over the past year, PTGX annual EBITDA has changed by +$346.08M (+383.08%)
What is Protagonist Therapeutics quarterly EBITDA?
The current quarterly EBITDA of PTGX is -$19.07M
What is the all time high quarterly EBITDA for Protagonist Therapeutics?
Protagonist Therapeutics all-time high quarterly EBITDA is $206.54M
What is Protagonist Therapeutics quarterly EBITDA year-on-year change?
Over the past year, PTGX quarterly EBITDA has changed by -$225.62M (-109.23%)
What is Protagonist Therapeutics TTM EBITDA?
The current TTM EBITDA of PTGX is $30.12M
What is the all time high TTM EBITDA for Protagonist Therapeutics?
Protagonist Therapeutics all-time high TTM EBITDA is $255.74M
What is Protagonist Therapeutics TTM EBITDA year-on-year change?
Over the past year, PTGX TTM EBITDA has changed by -$121.27M (-80.10%)